Erschienen in:
04.01.2016 | Original Article
The impact of chemotherapy for breast cancer on sexual function and health-related quality of life
verfasst von:
Juliane Farthmann, A. Hanjalic-Beck, J. Veit, B. Rautenberg, E. Stickeler, T. Erbes, M. Földi, A. Hasenburg
Erschienen in:
Supportive Care in Cancer
|
Ausgabe 6/2016
Einloggen, um Zugang zu erhalten
Abstract
Purpose
In this prospective trial, we evaluated the influence of chemotherapy for breast cancer on women’s health-related quality of life (HR-QoL), sexual function, and mental status.
Methods
The patients completed validated questionnaires on HR-QoL, sexual function, and depression before, during, and at the end and finally 6 months after chemotherapy. Special attention was paid to possible differences between pre- and postmenopausal patients.
Results
Between 2008 and 2012, 79 patients were enrolled in the trial (mean age 47.46 years). Premenopausal participants were 63.3 %. Sexual activity dropped from 71.9 % before chemotherapy to a minimum of 47 % at the end of chemotherapy. A similar effect was seen for pleasure and discomfort. Depression values were the highest at the beginning of chemotherapy, with spontaneous improvement in many patients during the course of time. HR-QoL and global health status both increased 6 months after therapy. For almost all parameters, changes were more obvious in pre- than in postmenopausal patients.
Conclusions
In a close monitoring, we observed significant changes in HR-QoL, depression, and sexual function in breast cancer patients. Special attention needs to be paid to premenopausal patients. The knowledge of effective recovery and spontaneous improvement of HR-QoL in spite of still impaired sexuality are important information in counseling both pre- and postmenopausal patients with diagnosis of breast cancer prior to upcoming therapy.